Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
MediciNova, Inc. (MNOV) generates frequent news as a clinical-stage biopharmaceutical company advancing late-stage small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Company announcements emphasize progress in its two core programs, MN-166 (ibudilast) and MN-001 (tipelukast), across multiple serious conditions.
News updates commonly cover clinical trial milestones, such as completion of patient enrollment, trial design details, and presentations at major scientific meetings. Examples include the COMBAT-ALS Phase 2b/3 trial of MN-166 in amyotrophic lateral sclerosis, the OXTOX study in chemotherapy-induced peripheral neuropathy, and the MN‑001‑NATG‑202 Phase 2 trial in hypertriglyceridemia and non-alcoholic fatty liver disease due to type 2 diabetes.
Investors and observers can also expect scientific and mechanistic updates, including peer-reviewed publications on MN-001 and its metabolite MN-002 in cholesterol and lipid metabolism, as well as letters from the CEO explaining how new data support the company’s development strategy. Regulatory and advisory appointments, such as the addition of experienced clinical and regulatory advisors, are another regular theme in MediciNova’s news flow.
Because MediciNova is listed on Nasdaq and the Tokyo Stock Exchange, its news often includes capital markets and investor relations events, such as conference presentations and corporate overviews for institutional and individual investors. This news page aggregates these developments so readers can follow clinical progress, scientific publications, regulatory interactions, and corporate updates related to MNOV in one place.
MediciNova (NASDAQ:MNOV) has announced promising results from a study presented by Dr. Justin Lathia at the Society for Neuro-Oncology's annual meeting regarding the efficacy of MN-166 (ibudilast) in combination with PD-1 inhibitors for treating glioblastoma (GBM). The study demonstrated a median survival increase from 28 days with PD-1 alone to 66 days when combined with MN-166, a significant finding (p<0.001). MediciNova aims to progress to clinical trials based on these encouraging outcomes, underscoring the potential of MN-166 to enhance GBM treatment.
MediciNova, Inc. (NASDAQ:MNOV) announced a study by Dr. Masatsune Ogura, revealing MN-001 (tipelukast) reduces triglyceride (TG) synthesis in liver cells. Presented at The Liver Meeting 2021, findings indicate that MN-001 inhibits TG synthesis by suppressing CD36 expression, a fatty acid transporter, in HepG2 cells. Compared to untreated cells, TG synthesis increased significantly with arachidonic acid and LXR agonist T0901317. MN-001 shows potential in addressing nonalcoholic steatohepatitis (NASH) by improving lipid metabolism.
MediciNova, Inc. (NASDAQ:MNOV) announced promising findings regarding MN-166 (ibudilast) in a uveal melanoma model presented by Dr. Grazia Ambrosini at the 10th Annual CURE OM Global Science Meeting. The study indicated that MN-166 significantly reduced migration of UM cells and prevented metastasis in mice. Key mechanisms involve macrophage migration inhibitory factor (MIF). This data positions MN-166 as a potential preventive treatment for uveal melanoma, addressing critical unmet needs in this area. The company aims to proceed to clinical trials to evaluate MN-166's efficacy in combating cancer metastasis.
MediciNova, Inc. (NASDAQ:MNOV) announced that Dr. Justin Lathia from the Cleveland Clinic will present new findings on MN-166 (ibudilast) in a glioblastoma animal model at the 26th Annual Meeting of the Society for Neuro-Oncology in Boston, scheduled for November 18-21, 2021. The presentation will occur on November 20, focusing on the role of myeloid cells in glioblastoma. MN-166 is a compound in late-stage clinical development for various neurodegenerative diseases and conditions, showcasing its potential in a range of therapeutic areas.
MediciNova, Inc. (NASDAQ: MNOV) announced the selection of an abstract showcasing MN-001 (tipelukast) at the 19th International Symposium on Atherosclerosis (ISA2021) from October 24-27, 2021. The study reveals that MN-001 inhibits arachidonic acid uptake, thereby reducing triglyceride (TG) synthesis in hepatocytes by down-regulating CD36 expression. Dr. Masatsune Ogura will present the findings online post-conference. Previously, MN-001 demonstrated significant TG reduction in clinical trials, showing potential for treating conditions like NASH. MediciNova continues its focus on developing therapies for inflammatory and fibrotic diseases.
MediciNova, a biopharmaceutical company (NASDAQ:MNOV), will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference from September 9-15, 2021. CEO Yuichi Iwaki and VP Geoffrey O'Brien will hold one-on-one meetings, with investor requests facilitated through Morgan Stanley. MediciNova develops therapies for inflammatory and neurodegenerative diseases, with its lead asset MN-166 in Phase 3 trials for ALS and DCM. The company has a diverse pipeline, with additional clinical programs underway for multiple conditions.
MediciNova, Inc. (NASDAQ: MNOV) announced that an abstract titled Improvement of Intracellular Lipid Metabolism by Tipelukast in the Pathogenesis of NASH/NAFLD will be presented at The Liver Meeting® 2021, occurring from November 12-15, 2021. Dr. Masatsune Ogura from Chiba University will present findings on MN-001's (tipelukast) effects on lipid metabolism, notably its ability to suppress triglyceride synthesis and lower serum triglyceride levels. MN-001 aims to treat NASH/NAFLD through novel anti-inflammatory and anti-fibrotic mechanisms, with additional potential applications in various fibrotic diseases.
MediciNova, a biopharmaceutical company (NASDAQ:MNOV), announced the acceptance of an abstract regarding its Phase 2b/3 trial of MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS) at the 32nd International Symposium on ALS/MND, set for December 7-10, 2021. The presentation will be led by Chief Medical Officer Kazuko Matsuda. The COMBAT-ALS trial aims to assess efficacy and safety with 230 participants across the U.S., Canada, and Europe. MN-166 is also in development for other neurodegenerative diseases and conditions like glioblastoma and ARDS.
MediciNova, Inc. (NASDAQ: MNOV) reported significant advancements in its drug development pipeline in its Q2 2021 update. The company initiated preclinical studies for MN-166 (ibudilast) targeting chlorine gas-induced lung disease, with positive Phase 2 results in alcohol use disorder published in Nature Journal, reinforcing MN-166's safety and potential. Ongoing patient enrollment continues for the Phase 3 trial of MN-166 in amyotrophic lateral sclerosis (ALS). Financially, MediciNova reported a cash balance of $77.8 million, projected to support operations through 2022.
MediciNova, trading on NASDAQ under the symbol MNOV, announced it received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering MN-166 (ibudilast) for treating ophthalmic diseases. This patent could extend protection until at least October 2039 and includes claims for treating macular injury. The drug is also in late-stage clinical trials for various neurodegenerative diseases, with encouraging results from previous studies. The patent may enhance MN-166's commercialization potential.